Vir Biotechnology, Inc. (VIR)
- Previous Close
6.12 - Open
6.12 - Bid 6.04 x 200
- Ask 6.10 x 200
- Day's Range
5.95 - 6.21 - 52 Week Range
4.95 - 14.45 - Volume
874,460 - Avg. Volume
1,223,600 - Market Cap (intraday)
839.429M - Beta (5Y Monthly) 1.14
- PE Ratio (TTM)
-- - EPS (TTM)
-3.83 - Earnings Date May 7, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
31.12
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
www.vir.bioRecent News: VIR
View More
Performance Overview: VIR
Trailing total returns as of 5/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VIR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VIR
View MoreValuation Measures
Market Cap
839.43M
Enterprise Value
31.97M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
13.00
Price/Book (mrq)
0.73
Enterprise Value/Revenue
0.50
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-19.72%
Return on Equity (ttm)
-38.09%
Revenue (ttm)
74.2M
Net Income Avi to Common (ttm)
-521.96M
Diluted EPS (ttm)
-3.83
Balance Sheet and Cash Flow
Total Cash (mrq)
905.35M
Total Debt/Equity (mrq)
8.51%
Levered Free Cash Flow (ttm)
-363.38M
Research Analysis: VIR
View MoreResearch Reports: VIR
View MoreWhat does Argus have to say about VIR?
VIR BIOTECHNOLOGY INC has an Investment Rating of HOLD; a target price of $6.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetWhat does Argus have to say about VIR?
VIR BIOTECHNOLOGY INC has an Investment Rating of HOLD; a target price of $6.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetRating decreased to a HOLD
VIR BIOTECHNOLOGY INC has an Investment Rating of HOLD; a target price of $6.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetRating increased to a BUY
VIR BIOTECHNOLOGY INC has an Investment Rating of BUY; a target price of $6.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target